Compare AAPG & AORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAPG | AORT |
|---|---|---|
| Founded | 2009 | 1984 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2024 | 1996 |
| Metric | AAPG | AORT |
|---|---|---|
| Price | $16.00 | $25.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $48.40 | ★ $49.40 |
| AVG Volume (30 Days) | 5.8K | ★ 570.8K |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.62 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $298,836,000.00 |
| Revenue This Year | $290.34 | $14.20 |
| Revenue Next Year | N/A | $11.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 18.01 |
| 52 Week Low | $16.03 | $19.16 |
| 52 Week High | $40.47 | $48.25 |
| Indicator | AAPG | AORT |
|---|---|---|
| Relative Strength Index (RSI) | 41.95 | 39.65 |
| Support Level | N/A | $22.83 |
| Resistance Level | $18.45 | $25.04 |
| Average True Range (ATR) | 0.35 | 1.00 |
| MACD | -0.08 | -0.30 |
| Stochastic Oscillator | 14.07 | 16.06 |
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.